Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:NTLA News 8 October 2025 - 9 January 2026

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) Reuters. (Nasdaq closes on Oct 31 showed ~$63.99 Reuters.) Over the past month CRSP has gained roughly 17% Genengnews, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced Genengnews. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative Investing. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals Investing, but the
2 November 2025
······
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR treatment nexiguran ziclumeran (NTLA-2001) due to a serious adverse event reuters.com. A patient in the Phase 3 MAGNITUDE study – which tests NTLA-2001 in transthyretin amyloidosis patients with cardiomyopathy (ATTR-CM) – experienced Grade 4 elevations in liver enzymes and bilirubin after receiving the one-time gene therapy reuters.com ca.investing.com. This met the trial’s pre-specified safety
27 October 2025
···
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 % at 36 monthsglobenewswire.com. Patients also showed clinical improvements or stabilization of neuropathy and cardiac markersglobenewswire.com, and safety findings were mostly mild infusion‑related eventsglobenewswire.com. CEO John Leonard said the data “demonstrate rapid, deep and durable TTR reductions with meaningful clinical improvements” and reiterated
8 October 2025
··

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Go toTop